Recently, the results of the pivotal Phase III clinical trial (EECOH-1) of ecnoglutide injection, developed by Sciwind ...
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily characterized by insulin resistance, β-cell dysfunction, and impaired ...
Sciwind Biosciences Co., Ltd. ("Sciwind"), a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, announced today that China's National ...
Little is known about the impacts of therapy on adolescent patients with T2DM. In a recent study, adolescents with newly diagnosed T2DM had profound impairment of beta-cell function, but treatment ...
Traditionally viewed as a primarily Western disease, diabetes is becoming a global threat. While dramatic improvements in emerging economies such as China and India are facilitating middle-class ...
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily characterized by insulin resistance, β-cell dysfunction, and impaired ...
A new study published in the journal of Medicine showed that both linagliptin and dapagliflozin have good safety profiles and ...
Polyneuropathy occurs when multiple peripheral nerves malfunction throughout the body. Neuropathy is a common complication of type 2 diabetes mellitus (T2DM). Polyneuropathy occurs when there is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results